Medical/Pharmaceuticals
NaviFUS highlights clinical trial data and device capabilities at virtual International Focused Ultrasound Symposium
TAIPEI, Nov. 27, 2020 /PRNewswire/ -- The 7th International Focused Ultrasound Symposium organized by the U.S. Focused Ultrasound Foundation took place from 11/9 to 11/13 in virtual format this year due to the Covid-19 epidemic. During the 5-day conference, participants presented and exchanged in...
2020-11-27 12:21
1712
European Medicines Agency Validates Application for Tepotinib for the Treatment of Advanced NSCLC with METex14 Skipping Alterations
DARMSTADT, Germany, Nov. 27, 2020 /PRNewswire/ -- Merck, a leading science and technology company, today announced that the European Medicines Agency (EMA) has validated for review, the application for tepotinib for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) ...
2020-11-27 08:42
2604
Haoma Medica Completes First-in-Human Trial for NaQuinate, a Novel Treatment in Development for Osteoporosis
LONDON, Nov. 27, 2020 /PRNewswire/ -- Haoma Medica announced today the completion of a first-in-human trial for NaQuinate, a naphthoquinone carboxylic acid, which is being developed as a novel orally administered therapeutic for osteoporosis. The first-in-human trial initiated last year in heal...
2020-11-27 08:39
2449
Nose Filler Injection Can Cause Vision Loss When Injected With Poor Injection Techniques & Without Understanding Of Facial Anatomy, Dr Ivan Puah Warns
SINGAPORE, Nov. 26, 2020 /PRNewswire/ -- Dermal fillers using hyaluronic acid is one of the common types of soft-tissue augmentation used inSingapore for nose enhancement. Medical Director of Amaris B. Clinic, DrIvan Puah warns that when inexperienced medical injectors or non-medical professio...
2020-11-26 22:07
2722
Luye Pharma and Distriphil Enter Exclusive Distribution Partnership in the Philippines with Joint Commitment to Raising Mental Health Awareness
* Luye Pharma grants Distriphil exclusive distribution and marketing rights for Seroquel® and Seroquel XR® in the Philippines * Two companies pledge to make joint effort to raise awareness of mental health issues as part of the "We Care About Mental Health" initiative SHANGHAI, Nov. 26, 2020 ...
2020-11-26 16:44
6125
Singapore-based Hello Health Group announce appointment of John Davison as Vice-Chairman
SINGAPORE, Nov. 26, 2020 /PRNewswire/ -- Hello Health Group, a leading Digital Health company inAsia focusing on the development of health and wellness information platforms and services in local languages for consumers and patients, is excited to announce the appointment ofJohn Davison as Vice-...
2020-11-26 16:40
2938
Interim report, May-October 2020/21
STOCKHOLM, Nov. 26, 2020 /PRNewswire/ -- In Elekta's second quarter, we managed to perform better than the overall radiotherapy market both in terms of orders and revenue despite continuous challenging circumstances. We also improved margins and stabilized cash flow. The launch of our new Harmony...
2020-11-26 15:01
6671
Gustaf Salford appointed Elekta CEO by Board of Directors
STOCKHOLM, Nov. 26, 2020 /PRNewswire/ -- Elekta (EKTA-B.ST) announced today that Gustaf Salford has been appointed to the role of President and CEO, effective immediately. He has been Acting CEO since earlyJune 2020. Elekta's Board of Directors carried out an extensive search process, with the c...
2020-11-26 14:59
5861
Approval of Phase I/II Clinical Trial of ATG-016 (Eltanexor), a Second Generation Selective Inhibitor of Nuclear Export (SINE), in Mainland China for the Treatment of Myelodysplastic Syndrome
SHANGHAI and HONG KONG, Nov. 26, 2020 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", HKSE stock code: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-inclass therapeutics in hematolog...
2020-11-26 14:04
5824
Approval of Phase I/II Clinical Trial of ATG-016 (Eltanexor), a Second Generation Selective Inhibitor of Nuclear Export (SINE), in Mainland China for the Treatment of Myelodysplastic Syndrome
SHANGHAI and HONG KONG, Nov. 26, 2020 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", HKSE stock code: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-inclass therapeutics in hematolog...
2020-11-26 10:32
5226
Sirtex Medical and China Grand Pharmaceutical announce SIR-Spheres® Y-90 resin microspheres milestone
SIR-Spheres® new drug application is accepted by the National Medical Products Administration of China WOBURN, Mass., Nov. 26, 2020 /PRNewswire/ -- Sirtex Medical ("Sirtex"), a leading manufacturer of targeted liver cancer therapies, announced today that Sirtex with the support of its shareh...
2020-11-26 01:17
1920
RhoVac's Prostate Cancer Drug Candidate, RV001, is granted Fast Track Designation by the FDA
LUND, Sweden, Nov. 25, 2020 /PRNewswire/ -- RhoVac, a clinical stage company today announced that the American FDA has granted Fast Track Designation to the company's drug candidate, RV001. Fast Track Designation is granted to investigational drugs for expedited review by the FDA, to facilitate ...
2020-11-25 16:06
1505
Ascentage Pharma Announces First Patient Dosed in Europe in the Phase Ib/II Study of the Bcl-2 inhibitor APG-2575 in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
SUZHOU, China and ROCKVILLE, Md., Nov. 25, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that a Phase Ib/II clinical ...
2020-11-25 08:27
2319
MedAlliance announces successful completion of enrolment in ISABELLA clinical trial for the treatment of failing AV fistulas in hemodialysis patients
NYON, Switzerland, Nov. 25, 2020 /PRNewswire/ -- MedAlliance has announced completion of patient enrolment in theISABELLA Clinical Trial with SELUTION SLR™ 018 DEB (drug-eluting balloon) for the treatment of dysfunctional AV fistulas in end-stage renal failure patients undergoing hemodialysis. SE...
2020-11-25 08:00
2506
Janssen Korea Ltd. and Johnson & Johnson Innovation Announce Awardees of the Seoul Innovation QuickFire Challenge on Healthcare for the New Normal in Collaboration with the Seoul Metropolitan Government and Korea Health Industry Development Institute
- Awardees DC Medical and deepmedi recognized for pioneering efforts leveraging data and health technologies to advance potentially life-saving ideas aimed at improving patient care during the COVID-19 pandemic and beyond. SEOUL, South Korea, Nov. 25, 2020 /PRNewswire/ -- Janssen Korea Ltd. and ...
2020-11-25 07:00
2795
RedHill Biopharma to Present at Evercore ISI HealthCONx and Piper Sandler Healthcare Conferences
TEL AVIV, Israel and RALEIGH, N.C., Nov. 25, 2020 /PRNewswire/ -- RedHill
Biopharma Ltd.
2020-11-25 07:00
2765
Almirall announces collaborations with the University of South Australia and Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
BARCELONA, Spain, Nov. 25, 2020 /PRNewswire/ -- AlmirallShare
2020-11-25 06:00
5696
Global Cord Blood Corporation Reports Financial Results for the Second Quarter and First Half of Fiscal 2021
HONG KONG, Nov. 25, 2020 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"),China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced its unaudited financial results for...
2020-11-25 05:16
12967
The cost of one dose of the Sputnik V vaccine will be less than $10 for international markets
RDIF continues expanding existing agreements with international manufacturing partners to produce the vaccine for more than 500 million people in 2021 MOSCOW, Nov. 25, 2020 * The cost of one dose of the Sputnik V vaccine for international markets will be less than$10. Sputnik V is a two dose ...
2020-11-25 04:38
1393
Second interim analysis of clinical trial data showed a 91.4% efficacy for the Sputnik V vaccine on day 28 after the first dose; vaccine efficacy is over 95% 42 days after the first dose
MOSCOW, Nov. 24, 2020 /PRNewswire/ -- * The efficacy of the Sputnik V vaccine is 91.4%, based on the second interim analysis of data obtained 28 days after administering the first dose (7 days after the second dose). * Calculation was based on the analysis of data on volunteers (n = 18,794) ...
2020-11-24 22:14
1441
Week's Top Stories
Most Reposted
QDX Co-Founder Giuseppe Barca Awarded Prestigious Gordon Bell Prize, Pioneering Advancements in Drug Discovery Technology
[Picked up by 301 media titles]
2024-11-26 18:49Southeast Asian Consumers Raise Online Security Concerns, New GSMA Survey Shows
[Picked up by 296 media titles]
2024-11-26 13:00ITAP 2024 sets the stage for a more connected advanced factory ecosystem with focus on AI, advanced robotics and sustainability
[Picked up by 288 media titles]
2024-11-28 17:24TAILG's First Flagship Store in Indonesia Grandly Opens
[Picked up by 283 media titles]
2024-11-22 21:59
MediSun Energy Raises $8.75M Seed Round with Vynn Capital to Drive MENA Expansion and Advance Osmotic Energy Innovation
[Picked up by 280 media titles]
2024-11-25 10:00
Most Read
Chinese path to modernization a model for Global South, experts say
2024-11-23 15:35
11468
SUNLU Formnext 2024 Event Highlights: From Functional Filaments to FilaDryer E2
2024-11-23 21:00
7513
Innovative technology and applications recognised with Hong Kong ICT Awards 2024
2024-11-23 02:02
7247
MMA SMARTIES Thailand 2024 - Celebrates Unparalleled Marketing Innovation and Excellence in Thailand
2024-11-23 11:00
6613
WeBank Powers Fusion Bank's Rapid Launch of a Next-Generation Core Banking System
2024-11-22 15:21
4964